

NEW SILKROUTES GROUP LIMITED AND ITS SUBSIDIARIES Registration Number: 199400571K

Condensed Interim Financial Statements For the Fourth Quarter and Full Year Ended 30 June 2021

Table of Contents

		Page
A.	Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income	1
B.	Condensed Interim Statements of Financial Position	3
C.	Condensed Interim Statements of Changes in Equity	5
D.	Condensed Interim Consolidated Statement of Cash Flows	8
E.	Notes to the Condensed Interim Consolidated Financial Statements	10
F.	Other Information Required by Listing Rule Appendix 7.2	29

CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Note	3 months ended 30 June 2021 US\$'000	3 months ended 30 June 2020 US\$'000 (Restated, note 8)	%	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000 (Restated, note 8)	%
Continuing operations:							
Revenue Other income Purchases of finished goods Changes in inventories of finished goods Employee benefits expense Amortisation of intangible assets Depreciation of property, plant and equipment Depreciation of right-of-use assets Other operating expenses Finance costs Share of results of an associate, net of tax	4	7,358 201 (4,027) 68 (2,083) (23) (23) 23 (698) (1,465) (528)	$22,262 \\ 854 \\ (11,173) \\ (471) \\ (1,802) \\ (68) \\ 246 \\ (239) \\ (12,685) \\ (101) \\ (7)$	-67% -76% -64% -114% 16% -66% -91% 192% -88% 423% -100%	42,039 1,823 (25,244) 69 (8,290) (106) (392) (1,390) (7,139) (913)	$49,529 \\ 1,626 \\ (28,312) \\ 228 \\ (8,608) \\ (274) \\ (102) \\ (1,176) \\ (14,218) \\ (833) \\ (7)$	-15% 12% -11% -70% -4% -61% 284% 18% -50% 10% -100%
(Loss)/profit before taxation Taxation	6 7	(1,174) (87)	(3,184) (108)	-63% -19%	457 (399)	(2,147) (457)	-121% -13%
(Loss)/profit from continuing operations for the period/year		(1,261)	(3,292)	-62%	58	(2,604)	-102%
Discontinued operation: Loss from discontinued operation, net of tax	8	(4,814)	(6,096)	-21%	(23,625)	(5,590)	323%
Loss for the period/year		(6,075)	(9,388)	-35%	(23,567)	(8,194)	188%

CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONT'D)

3 months ended 30 June 2021 US\$'000	3 months ended 30 June 2020 US\$'000 (Restated, note 8)	%	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000 (Restated, note 8)	%
-	(2,545)	-100%	-	(2,545)	-100%
52	(214)	-124%	1,622	(406)	-500%
52	(2,759)	-102%	1,622	(2,951)	-155%
(6,023)	(12,147)	-50%	(21,945)	(11,145)	97%
(1,454) (4,814)	(3,562) (6,096)	-59% -21%	(1,029) (23,625)	(3,409) (5,590)	-70% 323%
(6,268) 193	(9,658) 270	-35% -29%	(24,654) 1,087	(8,999) 805	174% 35% 188%
(1,267) (4,814)	(3,725) (8,641)	-55 % -66% -44%	408 (23,625)	(3,761) (8,135)	-111% 190%
(6,081)	(12,366)	-51%	(23,217)	(11,896)	95%
					69% 97%
(0.70)	(12,147)	-30 70	(0.49)	(11,145)	2170
	30 June 2021 US\$'000 52 52 (6,023) (1,454) (4,814) (6,268) 193 (6,075) (4,814) (6,081) 58 (6,023)	30 June 2021 30 June 2020 US\$'000 (Restated, note 8) - (2,545) 52 (214) 52 (214) (6,023) (12,147) (1,454) (3,562) (4,814) (6,096) (6,268) (9,658) 193 270 (6,075) (9,388) (1,267) (3,725) (4,814) (8,641) (6,081) (12,366) 58 219 (6,023) (12,147)	30 June 2021 USS'000 30 June 2020 USS'000 (Restated, note 8) % - (2,545) -100% 52 (214) -124% 52 (2,759) -102% (6,023) (12,147) -50% (1,454) (3,562) -59% (4,814) (6,096) -21% (6,268) (9,658) -35% 193 270 -29% (6,075) (9,388) -35% (1,267) (3,725) -66% (4,814) (8,641) -44% (6,081) (12,366) -51% (6,023) (12,147) -50%	30 June 2021 USS'000 30 June 2020 USS'000 (Restated, note 8) 30 June 2021 USS'000 - (2,545) -100% - 52 (214) -124% 1,622 52 (2,759) -102% 1,622 (6,023) (12,147) -50% (21,945) (1,454) (3,562) -59% (1,029) (4,814) (6,096) -21% (23,625) (6,075) (9,388) -35% (24,654) 193 270 -29% 1,087 (1,267) (3,725) -66% 408 (4,814) (8,641) -44% (23,625) (6,081) (12,366) -51% (23,217) (5,081) (12,366) -51% (23,217) (5,023) (12,147) -50% (21,945)	30 June 2021 USS'000 30 June 2020 (Restated, note 8) 30 June 2021 USS'000 30 June 2020 USS'000 30 June 2020 USS'000 - (2,545) - USS'000 (Restated, note 8) - (2,545) -100% - (2,545) 52 (214) -124% 1,622 (406) 52 (2,759) -102% 1,622 (2,951) (6,023) (12,147) -50% (21,945) (11,145) (1,454) (3,562) -59% (1,029) (3,409) (4,814) (6,096) -21% (23,625) (5,590) (6,268) (9,658) -35% (24,654) (8,999) 193 270 -29% 1,087 805 (1,267) (3,725) -66% 408 (3,761) (4,814) (8,641) -44% (23,625) (8,135) (6,081) (12,366) -51% (23,217) (11,896) 58 219 -74% 1,272 751 (6,023)

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

		Gro 30 June 2021	oup 30 June 2020	Company 30 June 2021 30 June 2020		
	Note	50 June 2021 US\$'000	30 June 2020 US\$'000	US\$'000	50 June 2020 US\$'000	
Non-current assets						
Property, plant and equipment		3,200	8,739	9	7	
Intangible assets	10	19,433	18,524	215	-	
Right-of-use assets		3,886	3,010	429	-	
Subsidiaries Financial asset at fair value		-	-	21,046	46,436	
through other comprehensive income		_	17,192	_	_	
Long-term receivables	11	353	1,751	_	_	
Deferred tax assets		37	183	-	-	
Total non-current assets		26,909	49,399	21,699	46,443	
Current assets						
Inventories		2,428	1,913	-	-	
Trade and other receivables	11	7,672	16,993	1,361	3,687	
Contract assets		-	3,933	-	-	
Prepayments		210	596	30	15	
Derivative financial instruments Cash and bank balances		- 6,609	1,495 19,323	72	432	
Fixed deposits		416	391	-	-	
Total current assets		17,335	44,644	1,463	4,134	
Total assets		44,244	94,043	23,162	50,577	
EQUITY AND LIABILITIES						
EQUITY						
Share capital	12	88,183	88,183	88,183	88,183	
Treasury shares Other reserves	13	(863) (2,613)	(863) (9,518)	(863) 45	(863) 45	
Accumulated losses		(70,485)	(45,831)	(71,160)	(43,283)	
		14,222	31,971	16,205	44,082	
Non-controlling interests		1,048	1,099	-	-	
Total equity		15,270	33,070	16,205	44,082	
Non-current liabilities						
Borrowings	14	3,992	14,906	-	-	
Lease liabilities Deferred tax liabilities		1,342 151	348 387	277	-	
Other payables	15	5,735	4,877	-	-	
Total non-current liabilities		11,220	20,518	277	-	

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (CONT'D)

		Group			ipany
	Note	30 June 2021 US\$'000	30 June 2020 US\$'000	30 June 2021 US\$'000	30 June 2020 US\$'000
Current liabilities					
Trade and other payables	15	7,815	26,025	6,517	6,495
Contract liabilities		153	157	-	-
Borrowings	14	8,582	12,455	-	-
Lease liabilities		842	728	163	-
Derivative financial instruments		-	350	-	-
Current income tax payable		362	740	-	-
Total current liabilities		17,754	40,455	6,680	6,495
Total liabilities		28,974	60,973	6,957	6,495
Total equity and liabilities		44,244	94,043	23,162	50,577

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

<> Attributable to owners of the Company>										
Group	Share capital US\$'000	Treasury shares US\$'000	Foreign currency translation reserve US\$'000	Capital reserve US\$'000	Fair value reserve US\$'000	Other reserves US\$'000	Accumulated losses US\$'000	Total US\$'000	Non- controlling interests US\$'000	Total equity US\$'000
Balance as at 1 July 2020	88,183	(863)	(500)	45	(5,468)	(3,595)	(45,831)	31,971	1,099	33,070
Loss for the financial year Other comprehensive income	-	-	-	-	-	-	(24,654)	(24,654)	1,087	(23,567)
- Foreign currency translation differences	-	-	1,437	-		_	-	1,437	185	1,622
Total comprehensive loss for the financial year	-	-	1,437	-	-	-	(24,654)	(23,217)	1,272	(21,945)
Contributions by and distributions to owners										
- Loss of control of subsidiaries	-	-	-	-	5,468	-	-	5,468	-	5,468
Capital reductionDividends	-	-	-	-	-	-	-	-	(62) (1,261)	(62) (1,261)
Transactions with owners in their own capacity as owners	-	-	-	-	5,468	-	-	5,468	(1,323)	4,145
Balance as at 30 June 2021	88,183	(863)	937	45	-	(3,595)	(70,485)	14,222	1,048	15,270

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

<> Foreign										
	Share capital	Treasury shares	currency translation reserve	Capital reserve	Fair value reserve	Other reserves	Accumulated losses	Total	Non- controlling interests	Total equity
Group										
Balance as at 1 July 2019	88,183	(863)	(148)	45	(2,923)	(3,596)	(36,864)	43,834	1,338	45,172
Loss for the financial year Other comprehensive loss:	-	-	-	-	-	-	(8,999)	(8,999)	805	(8,194)
- Changes in the fair value of equity										
investments at fair value through other comprehensive income	-	-	-	-	(2,545)	-	-	(2,545)	-	(2,545)
- Foreign currency translation			(252)							
differences Total comprehensive loss for the	-	-	(352)	-	-	-	-	(352)	(54)	(406)
financial year	-	-	(352)	-	(2,545)	-	(8,999)	(11,896)	751	(11,145)
Contributions by and distributions to owners										
- Effects of acquiring of non-										
controlling interest in a subsidiary	-	-	-	-	-	-	32	32	(132)	(100)
 Deregistration/disposal of subsidiaries 	-	-	-	-	-	1	-	1	-	1
- Dividends	-	-	-	-	-	-	-	-	(858)	(858)
Transactions with owners in their own capacity as owners	-	-	-	-	-	1	32	33	(990)	(957)
Balance as at 30 June 2020	88,183	(863)	(500)	45	(5,468)	(3,595)	(45,831)	31,971	1,099	33,070

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

	Share capital US\$'000	Treasury shares US\$'000	Capital reserve US\$'000	Accumulated losses US\$'000	Total equity US\$'000
Company					
Balance as at 1 July 2020 Loss for the year, representing total comprehensive loss for the	88,183	(863)	45	(43,283)	44,082
financial year	-	-	-	(27,877)	(27,877)
Balance as at 30 June 2021	88,183	(863)	45	(71,160)	16,205
Company					
Balance as at 1 July 2019 Loss for the year, representing total comprehensive loss for the financial year	88,183	(863)	45	(39,310)	48,055
financial year Balance as at 30 June 2020	-	-	-	(3,973)	(3,973)
Datatice as at 50 June 2020	88,183	(863)	45	(43,283)	44,082

CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

		oup
	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000
Cash flows from operating activities		
Profit/(loss) before taxation:		
- from continuing operations	457	(2,147)
- from discontinuing operation	(23,637)	(5,626)
	(23,180)	(7,773)
Adjustments for:		
Amortisation of intangible assets	106	274
Depreciation of property, plant and equipment	1,904	1,300
Depreciation of right-of-use assets	1,475	1,346
Impairment loss on intangible assets	-	1,004
Interest expense	1,920	2,769
Interest income	(125)	(94)
Net fair value (gain)/loss on derivative financial		
instruments	(2)	233
Net present value change of the call and put option	050	1 001
liability Reversal of allowance for inventories obsolescence	858	1,281
	-	(254)
Impairment losses recognised on trade and other receivables	537	7,289
Fair value loss on financial assets at fair value through	551	7,207
profit or loss	21,079	-
Plant and equipment written off	24	-
Share of results of associates	-	7
Unrealised foreign exchange differences	108	(385)
Operating cash flows before working capital changes:	4,704	6,997
Changes in inventories	(629)	(3)
Changes in trade and other receivables	5,386	5,698
Changes in contract assets	3,933	14,355
Changes in prepayments	256	230
Changes in trade and other payables	(16,685)	(20,287)
Changes in contract liabilities	(5)	2
Cash (used in)/from operations	(3,040)	6,992
Income tax paid	(855)	(400)
Net cash (used in)/generated from operating activities	(3,895)	6,592

CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS (CONT'D)

	Group		
	12 months ended	12 months ended	
	30 June 2021	30 June 2020	
	US\$'000	US\$'000	
Cash flows from investing activities			
Acquisition of intangible assets	(215)	-	
Interest received	125	61	
Purchase of property, plant and equipment	(2,345)	(150)	
Net cash used in investing activities	(2,435)	(89)	
Cash flows from financing activities			
Acquisition of non-controlling interests in a subsidiary	-	(101)	
Capital reduction paid to non-controlling interests of the			
subsidiaries	(62)	-	
Dividends paid to the non-controlling interests of the			
subsidiaries	(1,261)	(858)	
Fixed deposits pledged	-	49	
Interest paid	(1,210)	(2,669)	
Proceeds from loans	4,768	36,323	
Proceeds from financing of vessel, net of transaction costs	-	4,614	
Restricted cash	2,258	8,827	
Repayment of loans	(8,973)	(41,299)	
Repayment of lease liabilities	(1,242)	(1,046)	
Net cash (used in)/generated from financing activities	(5,722)	3,840	
Net (decrease)/increase in cash and cash equivalents	(12,052)	10,343	
Cash and cash equivalents at beginning of financial year	17,065	6,821	
Exchange differences on translation of cash and		•	
cash equivalents	1,596	(99)	
Cash and cash equivalents at end of financial year	6,609	17,065	

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1 Corporate information

New Silkroutes Group Limited (the "Company") (Co. Reg. No. 199400571K) is incorporated and domiciled in Singapore. The address of its registered office and principal place of business is at 456 Alexandra Road, #19-02 Fragrance Empire Building, Singapore 119962. The Company is listed on the Singapore Exchange Securities Trading Limited. These condensed interim consolidated financial statements as at and for the three months ended 30 June 2021 comprise the Company and its subsidiaries (collectively, the "Group").

The principal activities of the Company are that of investment holding Company. The principal activities of the Group are:

- (a) Distributors of health supplements and Chinese proprietary medicine, providers of clinical management services, and healthsciences consultants;
- (b) Dental services;
- (c) General medical services and aesthetic clinic;
- (d) Medical and dental supplies;
- (e) Manufacture of non-woven fabric;
- (f) Management services and investment holding.

2 Basis of preparation

The condensed interim financial statements are for the three months ended 30 June 2021 have been prepared in accordance with SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last audited financial statements for the year ended 30 June 2020.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in United States dollars ("USD" or "US\$"), which is the Company's functional currency and all values in the tables are rounded to the nearest thousand (US\$'000), except when otherwise indicated.

Going concern assumptions

The condensed interim financial statements have been prepared on a going concern basis notwithstanding that the Group's current liabilities exceeds its current assets by US\$419,000 as at 30 June 2021 as the Directors are of the view that the Group will continue to operate as a going concern after considering the following:

- (a) The Group contributed US\$42,039,000 to the revenue for the financial year ended 30 June 2021. The Group can continue to grow its healthcare operations based on the financials from its operating subsidiaries.
- (b) The Group's current liabilities comprised the guaranteed profit of US\$3,024,000 (S\$4,000,000) was received by the Company which is accounted as an advance receipt under other payables in the statement of financial position and does not constitute an actual cash or payable obligation on the Group.

2 Basis of preparation (cont'd)

Going concern assumptions (cont'd)

(c) As at the reporting period end, the Group has undrawn borrowings facilities of US\$756,000 that is available.

The Directors are of the opinion that the above considerations would allow the Group to generate sufficient cash flows from its operations and meet its obligations as and when they fall due.

If the Group is unable to continue operational existence for the foreseeable future, the Group may be unable to discharge its liabilities in the normal course of business and adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are currently recorded in the statements of financial position. In addition, the Group may have to reclassify non-current assets and liabilities as current assets and liabilities. No such adjustments have been made to these interim financial statements.

2.1 New and amended standards adopted by the Group

A number of amendments to Standards has become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the financial year ended 30 June 2020.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements:

• Control over Shanghai Fengwei Garment Accessory Co., Ltd. (the "Shanghai Fengwei")

Pursuant to the Management Agreement, the Company assigned the management rights and the profits of Shanghai Fengwei during the period from 1 January 2020 to 31 December 2021 to a company incorporated in the People's Republic of China ("Entity"). All post-tax profits or losses during the aforesaid period, whether in excess of or less than the Consideration, shall be attributable to or borne by the Entity. In return, the Entity would retain the net profit or loss after tax generated by Shanghai Fengwei from 1 January 2020 to 31 December 2021.

2 Basis of preparation (cont'd)

2.2 Use of judgements and estimates (cont'd)

• Control over Shanghai Fengwei (cont'd)

The directors and management of the Company made an assessment that Shanghai Fengwei's management continues to manage the operations and business activities of Shanghai Fengwei and that the Group has control over Shanghai Fengwei in accordance with the definition of control and the related guidance set out in SFRS(I) 10 *Consolidated Financial Statements*. Accordingly, Shanghai Fengwei remains a subsidiary of the Group.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial period are included in the following notes:

• Impairment of trade and other receivables and contract assets

The Group and the Company shall recognise in profit or loss the expected credit losses on its trade and other receivables and contract assets which involves management's estimation on the probability of default and loss given default. The Group uses judgement in making these assumptions and selecting the inputs to the impairment calculation, based on the Group's past history, existing market conditions as well as forward looking estimates at the end of each reporting period.

The identification of the loss allowance requires use of judgement and estimates. Where the expectation is different from the original estimate, such difference will have an impact on the carrying amount of the trade and other receivables and contract assets and loss allowance in the period in which such estimate has been changed.

• Impairment test for cash-generating unit containing goodwill and intangible assets

A cash-generating unit ("CGU") to which goodwill has been allocated shall be tested for impairment annually, and whenever there is an indication that the unit may be impaired, by comparing the carrying amount of the CGU, including the goodwill, with the recoverable amount of the CGU. The recoverable amount is the higher of the CGU's fair value less costs of disposal and its value in use. Where the recoverable amount of the CGU is less than its carrying amount, such impairment loss is recognised in profit or loss.

Significant judgement and estimates by management are required in assessing: (i) whether the carrying amount of the CGU can be supported by its market value based on comparable assets or the net present value of future cash flows which are estimated based upon the continued use of the assets in the business; and (ii) the appropriate key assumptions to be applied in preparing cash flow projections including whether these cash flow projections are extrapolated using a suitable growth rate and then discounted using an appropriate discount rate. Changing the assumptions selected by management to determine the level of impairment, including the growth rate and discount rate assumptions in the cash flow projections, could materially affect the net present value used in the impairment test and as a result may potentially affect the Group's results. The carrying amounts of the Group's intangible assets, including goodwill, at the end of the reporting period, and the basis and assumptions used to determine the recoverable amount of the CGU, are disclosed in Note 10.

3 Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4 Segment and revenue information

For management purposes, the Group is organised into business units based on their products and services, and has three reportable operating segments as follows:

- Healthcare owns and operates clinics in Singapore providing complementary integrative therapies, runs employee healthcare benefits programmes, offers systems integration services to hospitals and healthcare facilities, owns and operates clinics in Singapore providing dental services, and distributes dental and medical supplies, and manufacturing of healthcare consumables.
- Others general corporate activities and others
- Trading of oil and gas trading in petrochemical products, power generation, investments in strategic petrochemical assets globally, and to develop a trading hub for energy products between Europe and Asia. This segment has been classified as discontinued operation in current financial year (Note 8).

The Group's executive directors monitor the operating results of its operating segments for the purpose of making decisions about resource allocation and performance assessment.

Information regarding the results of each reportable segment is included in the following table. Performance is measured based on segment profit/(loss) before taxation, as included in the internal management reports that are regularly reviewed by the Group's executive directors. Segment profit/(loss) is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

4 Segment and revenue information (cont'd)

4.1 Reportable segments

1 April 2021 to 30 June 2021	Healthcare US\$'000	Others US\$'000	Oil and gas (Discontinued operation) US\$'000	Adjustments US\$'000	Per consolidated financial statements US\$'000
Segment revenue - Sales to external customers	7,358		-	-	7,358
Segment results - Other income - Amortisation of	182	19	-	-	201
intangible assetsDepreciation of property, plant and	(23)	-	-	-	(23)
equipment * - Depreciation of	(401)	42	-	-	(359)
rights-of-use assets - Other non-cash	(612)	(86)	-	-	(698)
items - Finance costs	(224) (122)	(62) (406)	(2,839)	2,839	(286) (528)
Segment loss	(675)	(586)	(4,814)	4,814	(1,261)
Segment assets and liabilities					
- Segment assets	42,343	1,901	-	-	44,244
- Segment liabilities	22,475	6,499	-	-	28,974
- Capital expenditure	(18)	(1)	-	-	(19)

* Comprises depreciation of property, plant and equipment included in changes in inventories of finished goods

4 Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

1 April 2020 to 30 June 2020	Healthcare US\$'000	Others US\$'000	Oil and gas (Discontinued operation) US\$'000	Adjustments US\$'000	Per consolidated financial statements US\$'000
Segment revenue - Sales to external customers	22,262	-	34,623	(34,623)	22,262
Segment resultsOther incomeAmortisation of intangible assets	722 (68)	132	836	(836)	854 (68)
 Depreciation of property, plant and equipment * Depreciation of 	212	(1)	(410)	410	211
rights-of-use assets - Net fair value on derivative financial instruments	(239)	- 207	(43) (156)	43 156	(239) 207
 Other non-cash items Finance costs Segment loss 	(808) (241) (176)	(1,315) 140 (3,116)	(5,599) (588) (6,096)	5,599 588 6,096	(2,123) (101) (3,292)
Segment assets and liabilities - Segment assets - Segment liabilities - Capital expenditure	46,419 27,549	1,572 4,999	46,052 28,425 (1)	- - 1	94,043 60,973

* Comprises depreciation of property, plant and equipment included in changes in inventories of finished goods

4 Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

1 July 2020 to 30 June 2021	Healthcare US\$'000	Others US\$'000	Oil and gas (Discontinued operation) US\$'000	Adjustments US\$'000	Per consolidated financial statements US\$'000
Segment revenue - Sales to external					
customers	42,039	-	18,397	(18,397)	42,039
Segment results					
- Other income - Amortisation of	1,736	87	45	(45)	1,823
 Amontsation of intangible assets Depreciation of property, plant and 	(106)	-	-	-	(106)
equipment * - Depreciation of	(1,601)	(4)	(299)	299	(1,605)
 rights-of-use assets Net fair value on derivative financial 	(1,304)	(86)	(85)	85	(1,390)
instruments - Other non-cash	-	-	2	(2)	-
items	(529)	(342)	(2,755)	2,755	(871)
- Finance costs	(495)	(418)	(1,008)	1,008	(913)
Segment profit/(loss)	744	(686)	(23,625)	23,625	58
Segment assets and liabilities					
- Segment assets	42,343	1,901	-	-	44,244
- Segment liabilities	22,475	6,499	-	-	28,974
- Capital expenditure	(2,003)	(5)	(336)	336	(2,008)

* Comprises depreciation of property, plant and equipment included in changes in inventories of finished goods

4 Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

1 July 2019 to 30 June 2020	Healthcare US\$'000	Others US\$'000	Oil and gas (Discontinued operation) US\$'000	Adjustments US\$'000	Per consolidated financial statements US\$'000
Segment revenue - Sales to external customers	49,529	-	325,439	(325,439)	49,529
Segment results - Other income - Amortisation of	1,453	173	1,504	(1,504)	1,626
 intangible assets Depreciation of property, plant and equipment * 	(274) (590)	- (2)	- (709)	- 709	(274) (592)
 Depreciation of rights-of-use assets Net fair value on derivative financial 	(1,176)	-	(170)	170	(1,176)
instruments - Other non-cash	1	-	(234)	234	1
items - Finance costs Segment profit/(loss)	(838) (933) 1,786	(1,234) 100 (4,390)	(5,642) (1,936) (5,590)	5,642 1,936 5,590	(2,072) (833) (2,604)
Segment assets and liabilities					
 Segment assets Segment liabilities Capital expenditure 	46,419 27,549 (139)	1,572 4,999 (7)	46,052 28,425 (4)		94,043 60,973 (150)

* Comprises depreciation of property, plant and equipment included in changes in inventories of finished goods

4.2 Disaggregation of revenue

Continuing operations:	3 months	3 months	12 months	12 months
	ended	ended	ended	ended
	30 June 2021	30 June 2020	30 June 2021	30 June 2020
	US\$'000	US\$'000	US\$'000	US\$'000
Healthcare products	4,444	20,350	28,992	37,913
Healthcare services	2,914	1,912	13,047	11,616
	7,358	22,262	42,039	49,529

4 Segment and revenue information (cont'd)

4.2 Disaggregation of revenue (cont'd)

Geographical information:

	3 months ended 30 June 2021 US\$'000	3 months ended 30 June 2020 US\$'000	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000
Australia	13	-	89	67
Bahrain	-	-	774	-
Cambodia	-	19,248	16,809	108,089
China	4,444	20,436	28,999	38,011
India	-	6	-	2,454
Portugal	-	-	814	-
Singapore	2,901	15,834	12,950	221,928
South Korea	-	35	-	722
Switzerland	-	1,326	-	1,326
United Arab Emirates	-	-	-	2,367
Vietnam	-	-	1	4
Discontinued operation	-	(34,623)	(18,397)	(325,439)
-	7,358	22,262	42,039	49,529

A breakdown of sales and operating loss after tax:

	30 June 2021	30 June 2020	Increase ((Decrease)
	US\$'000	US\$'000	/(Decrease) %
Sales reported for the first half year:Continuing operationsDiscontinuing operation	25,562 18,397	17,192 217,140	49% (92%)
 Operating loss after tax before deducting non- controlling interests reported for first half year: Continuing operations Discontinuing operation 	1,009 (2,337)	367 232	175% (1107%)
Sales reported for the second half year:Continuing operationsDiscontinuing operation	16,477	32,337 108,299	(49%) (100%)
Operating loss after tax before deducting non- controlling interests reported for second half year: - Continuing operations - Discontinuing operation	(951) (21,288)	(2,971) (5,822)	(68%) 266%

5 Financial assets and financial liabilities

5.1 Categories of financial instruments

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 June 2021 and 30 June 2020:

	Group		Company	
	30 June 2021 30 US\$'000	30 June 2020 US\$'000	30 June 2021 US\$'000	30 June 2020 US\$'000
Financial assets	039 000	039 000	039 000	039 000
Derivative financial instruments	-	1,495	-	-
Financial asset at fair value				
through other comprehensive		17 100		
income	-	17,192	-	-
Financial assets at amortised cost	15,050	38,458	1,433	4,119
Financial liabilities				
Derivative financial instruments	-	350	-	-
Lease liabilities	2,184	1,076	440	-
Financial liabilities at fair value				
through profit or loss	5,735	4,877	-	-
Financial liabilities at amortised				
cost	20,389	53,386	6,517	6,495

5.2 Fair value of financial assets and financial liabilities

The carrying amounts of cash and bank balances, trade and other receivables, trade and other payables and short-term borrowings approximate their respective fair values due to relatively short-term maturity of these financial instruments. Management has assessed that the effect of discounting the non-current long-term receivables to be insignificant and the carrying amount approximates its fair values.

5.3 Financial assets and liabilities measured at fair value

The Group classifies financial assets and liabilities measured at fair value using a fair value hierarchy which reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- a) Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);
- b) Inputs other than quoted prices included within Level 1 which are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices) (Level 2); and
- c) Inputs for the assets or liability which are not based on observable market data (observable inputs) (Level 3).

5 Financial assets and financial liabilities (cont'd)

5.3 Financial assets and liabilities measured at fair value (cont'd)

Financial assets:	Level 1 US\$'000	Level 2 US\$'000	Level 3 US\$'000	Total US\$'000
i manciai assets.				
 30 June 2021 Derivative financial instruments: Oil commodity futures Financial asset at fair value through other comprehensive income 	-	-	-	-
 30 June 2020 Derivative financial instruments: Oil commodity futures Financial asset at fair value through other comprehensive 	-	1,495	-	1,495
income	-	17,192	-	17,192
Financial liability:				
 30 June 2021 Derivative financial instruments: Oil commodity futures Financial asset at fair value through profit or loss 	-	-	-	-
- Other payables	-	-	5,735	5,735
 30 June 2020 Derivative financial instruments: Oil commodity futures Financial asset at fair value through profit or loss 	-	350	-	350
- Other payables	-	-	4,877	4,877

6 (Loss)/profit before taxation from continuing operations

6.1 Significant items

<u>Group</u>	3 months ended 30 June 2021 US\$'000	3 months ended 30 June 2020 US\$'000	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000
Impairment loss recognised on trade and other receivables Impairment loss on intangible assets	537	1,192 1,004	537	1,192 1,004
Net present value change of the call and put option liability Reversal of allowances for	858	1,281	858	1,281
inventories obsolescence Consultancy and marketing fees	-	7,683	3,990	(254) 7,683

6.2 Related party transactions

Other than as disclosed elsewhere in the interim financial statements, the following related party transactions took place between the Group and related parties during the financial period/year on terms agreed by the parties concerned:

Group	3 months ended 30 June 2021 US\$'000	3 months ended 30 June 2020 US\$'000	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000
Lease payments (rental) Consideration received on behalf	(139)	(85)	(454)	(256)
by a shareholder		-	-	2,828

7 Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

<u>Group</u>	3 months ended 30 June 2021 US\$'000	3 months ended 30 June 2020 US\$'000	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000
Current taxation: - Current period - Changes in estimates related to	121	189	535	628
prior years	(22)	117	(57)	117
Deferred taxation: - Origination and reversal of	99	306	478	745
temporary differences	(19)	(198)	(86)	(288)
Withholding tax expense	87	108	399	457

8 Loss from discontinued operation, net of tax

On 5 January 2021, the Company has commenced the winding up process of its wholly owned indirect subsidiary, International Energy Group Pte. Ltd. ("IEG") by way of creditors' voluntary liquidation, which was previously reported in the oil and gas segment. As such, the Group has lost control of IEG. Accordingly, the IEG and its subsidiaries were classified as discontinued operation of the Group and its assets and liabilities, deconsolidated from the Group. The comparative statements of comprehensive income are represented to show the discontinued operation separately from continuing operations.

Income statement disclosures

The results of IEG are as follows:

	3 months ended 30 June 2021 US\$'000	3 months ended 30 June 2020 US\$'000	12 months ended 30 June 2021 US\$'000	12 months ended 30 June 2020 US\$'000
Revenue and other income Expenses	-	35,459 (34,894)	18,442 (19,992)	326,943 (324,535)
Profit/(loss) from operations Finance costs Impairment loss from trade and	-	565 (588)	(1,550) (1,008)	2,408 (1,936)
other receivables Fair value loss on financial assets at fair value through profit or loss	- (4,814)	(6,098)	- (21,079)	(6,098)
Loss before tax from discontinued operation Taxation	(4,814)	(6,121) 25	(23,637) 12	(5,626) 36
Loss from discontinued operation, net of tax	(4,814)	(6,096)	(23,625)	(5,590)
Loss per share disclosures				

	3 months ended 30 June 2021 US\$	3 months ended 30 June 2020 US\$	12 months ended 30 June 2021 US\$	12 months ended 30 June 2020 US\$
Loss per share from discontinued operation attributable to owners of the Company (US cent)				
Basic and diluted	(2.31)	(2.92)	(11.33)	(2.68)

9 Net asset value

	Group		Company	
	30 June 2021	30 June 2020	30 June 2021	30 June 2020
Net asset value per ordinary share (US cent)	6.82	15.34	7.77	21.15

10 Intangible assets

Group	Goodwill US\$'000	Customer relationship US\$'000	Development costs US\$'000	Service right US\$'000	Trademark US\$'000	Development cost work in progress US\$'000	Total US\$'000
Cost:							
At 1 July 2019	18,353	274	1,544	88	330	-	20,589
Exchange difference on translation	(297)	-	-	(2)	-	-	(299)
At 30 June 2020 and 1 July 2020	18,056	274	1,544	86	330	-	20,290
Additions	-	-	-	-	-	215	215
Exchange difference on translation	800	-	-	6	-	-	806
At 30 June 2021	18,856	274	1,544	92	330	215	21,311
Accumulated amortisation and impairment:							
At 1 July 2019	-	25	386	46	33	-	490
Amortisation		26	154	28	66	-	274
Impairment loss	-	-	1,004	-	-	-	1,004
Exchange difference on translation	-	-	-	(2)	-	-	(2)
At 30 June 2020 and 1 July 2020	-	51	1,544	72	99	-	1,766
Amortisation	-	26	-	14	66	-	106
Exchange difference on translation	-	-	-	6	-	-	6
At 30 June 2021		77	1,544	92	165	-	1,878
Carrying amount: At 30 June 2021	18,856	197	-	-	165	215	19,433
At 30 June 2020	18,056	223	-	14	231	-	18,524

10 Intangible assets (cont'd)

Company	Development cost work in progress US\$'000
Cost:	
At 1 July 2019, 30 June 2020 and 1 July 2020	-
Additions	215
At 30 June 2021	215
Accumulated amortisation: At 1 July 2019, 30 June 2020 and 1 July 2020 Amortisation At 30 June 2021	
Carrying amount: At 30 June 2021	215
At 30 June 2020	

Impairment testing for a cash-generating unit containing goodwill

At the end of the reporting period, goodwill is attributable to the Group's cash-generating units ("CGUs") comprising (i) Healthsciences International Pte. Ltd. ("HSI"), (ii) Crescent Dental Clinic Pte. Ltd., Dentaltrendz JP Pte. Ltd., Trendz Dental Surgeons Pte. Ltd., L'ving Vine Dental Clinic Pte. Ltd., Dover Dental Surgery Pte. Ltd., Dentaltrendz Pte. Ltd. (collectively, the "Trendz" companies), (iii) Orange Orthodontics and Dentofacial Orthopaedics Pte. Ltd., Greedygums Pte. Ltd., Wren Dental and Medical Supplies Pte. Ltd. (collectively, the "Orange" companies), (iv) 84 INC Pte. Ltd., The Dental Hub@SG Pte. Ltd. and NDC Consulting Pte. Ltd. (collectively, the "TDH" companies), (v) Dr Chua's Family Clinic Pte. Ltd., HL Clinic Pte Ltd, HL Family Clinic & Surgery Pte. Ltd., HK Family Clinic & Surgery Pte. Ltd., HL Dermahealth Aesthetic Clinic Pte. Ltd. and Lily Aw Medical Services Pte Ltd (collectively, the "HSI Medical" companies) and (vi) Shanghai Fengwei Garment Accessory Co., Ltd. (the "Shanghai Fengwei") as follows:

	30 June 2021 US\$'000	30 June 2020 US\$'000
Cash-generating units		
HSI HSI Dental ⁽ⁱ⁾ HSI Medical Shanghai Fengwei	$ \begin{array}{r} 1,052 \\ 4,040 \\ 8,333 \\ 5,431 \\ \hline 18,856 \\ \end{array} $	1,052 3,779 7,794 5,431 18,056

⁽ⁱ⁾ Including Trendz, Orange and TDH CGUs.

10 Intangible assets (cont'd)

For the financial year ended 30 June 2021

For HSI, the recoverable amounts of the CGUs are determined by management are based on valuein-use ("VIU") calculations using management approved five-year cash flow forecasts. The key assumptions include average revenue growth of 11.5% (30.6.2020: 11.5%) and pre-tax discount 11.32% (30.6.2020: 9.66%), with 2% (30.6.2020: 2%) terminal growth rate.

HSI Dental sub-group, the recoverable amounts of the CGUs are determined by management are based on VIU calculations using management approved five-year cash flow forecasts. The key assumptions include average revenue growth of 6.5% (30.6.2020: 11.5%) and pre-tax discount 11.23% (30.6.2020: 9.66%), with 2% (30.6.2020: 2%) terminal growth rate.

For HSI Medical sub-group, the VIU calculation is based on the management approved five-year forecast of the Target Annual Audited Net Profit After Tax ("NPAT") at a pre-tax discount rate of 11.51% (30.6.2020: 9.66%) with 2% (30.6.2020: 2%) terminal growth rate.

Shanghai Fengwei's VIU calculation is determined based on management approved cash flow projections covering a five-year period, using an average growth rate of 7% (30.6.2020: 5%) pre-tax discount rate of 13.27% (30.6.2020: 12.82%) and a terminal growth rate of 2% (30.6.2020: 3%).

11 Trade and other receivables

	Gro 30 June 2021 US\$'000	oup 30 June 2020 US\$'000	Com 30 June 2021 US\$'000	pany 30 June 2020 US\$'000
Trade receivables from: Third parties Less: Loss allowance	6,086	17,075	-	-
Third parties	(75)	(4,167)	-	-
	6,011	12,908	-	-
Other receivables from:				
Former related party Related parties Subsidiaries	-	2,621 20	2,119	7 20 2,899
Loans to subsidiaries	363	409	102	632
Deposits Consideration receivables	2,311	2,311 278	2,311	2,311
Margin and hedge accounts Retention sum	-	1,625 823	-	-
Insurance recoverable Other receivables	900	825 1,922	6	-
Less: Loss allowance	3,574 (1,560)	10,009 (4,173)	4,538 (3,177)	5,869 (2,182)
	2,014	5,836	1,361	3,687
Total trade and other receivables	8,025	18,744	1,361	3,687
Represented by: Current Non-current	7,672 353	16,993 1,751	1,361	3,687
	8,025	18,744	1,361	3,687

12 Share capital

	30 June 2021		30 June 2020	
	Number of shares	Amount	Number of shares	Amount
Group and Company		US\$'000		US\$'000
<u>Issued and fully paid with no par</u> <u>value</u>				
At beginning and end of interim period	211,908,869	88,183	211,908,869	88,183

The number of issued shares excluding treasury shares as at the end of the interim period was 208,464,669 (30.6.2020: 208,464,669).

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at shareholders' meetings. All shares rank equally with regard to the Company's residual assets.

The Company's subsidiaries do not hold any shares in the Company as of 30 June 2021 and 30 June 2020.

13 Treasury shares

	30 June 2021		30 June 2020	
	Number of shares	Amount	Number of shares	Amount
Group and Company		US\$'000		US\$'000
<u>Issued and fully paid with no par</u> <u>value</u>				
At beginning and end of interim period	3,444,200	(863)	3,444,200	(863)

14 Borrowings

	Group	
	30 June 2021 US\$'000	30 June 2020 US\$'000
Amount repayable within one year or on demand Secured Unsecured	8,582	12,455
Amount repayable after one year Secured Unsecured	3,992	14,906
	12,574	27,361

14 Borrowings (cont'd)

Loan from financial institutions and other borrowings are secured by the following:

- i. Fixed deposits of the Group;
- ii. corporate guarantees by the Company and related parties;
- iii. charges over shares of certain subsidiaries of the Company;
- iv. personal guarantee(s) from a director of the Company and a former director of the Company and/or directors of subsidiaries;
- v. pledge over a director's land;
- vi. fixed and floating charge on all assets and undertakings of a subsidiary; and/or
- vii. certain property and equipment.

15 Trade and other payables

	Gr 30 June 2021 US\$'000	oup 30 June 2020 US\$'000	Com 30 June 2021 US\$'000	pany 30 June 2020 US\$'000
Trade payables from: Third parties Subsidiaries	662	9,557	-	- 89
	662	9,557	-	89
 Other payables from: Subsidiaries Former related party Accrued purchases Accrued operating expenses Accrued personnel expenses Deposit received Consideration payables Consultancy and marketing fees payable Advance receipt of profit guarantee Other payables 	35 1,183 401 7,247 - 3,024 998 12,888	35 3,670 765 176 354 6,291 4,485 2,828 2,741 21,345	2,381 35 180 183 - 3,024 714 6,517	1,589 35 191 50 354 - 1,268 2,828 91 6,406
Total trade and other payables	13,550	30,902	6,517	6,495
Represented by: Current Non-current	7,815 5,735 13,550	26,025 4,877 30,902	6,517 - 6,517	6,495 - 6,495

16 Contingent liabilities

The Company is alleged to be a corporate guarantor to a loan extended from OCAP Management Pte Ltd ("OCAP") to IEG. In January 2021, the Company has received letters of demand in respect of US\$7,158,133.33 from the provisional liquidators of OCAP.

IEG is alleged to be a corporate guarantor ("NSG Guarantee") to a lease financing arrangement of the bare boat charter agreement (the "BBC agreement") entered into by its subsidiary, TXZ Tankers Pte Ltd. The Company is alleged to be a corporate guarantor to the lease financing arrangement and the contingent liabilities therein. The Company had received a letter of demand dated 7 June 2021 from Iolani Shipping Limited ("Iolani") for an alleged sum of US\$10,695,760 plus any interest which is alleged to continue to accrue in accordance with the terms of the NSG Guarantee.

The Company has made no provision for any liability in connection with the foregoing claims in these interim financial statements. The management is in active discussion with OCAP and Iolani to reach an amicable conclusion.

17 Subsequent event

There are no known subsequent events which have led to adjustments to this set of condensed interim financial statements.

OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2

1. Review

The condensed consolidated statement of financial position of New Silkroutes Group Limited and its subsidiaries as of 30 June 2021 and the related condensed consolidated statement of comprehensive income for the three-month period and year then ended, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the year then ended and certain explanatory notes have not been audited or reviewed.

Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion: -

(a) Updates on efforts taken to resolve each outstanding audit issue

The auditors have issued a disclaimer of opinion on the Group's financial statements for the financial year ended 30 June 2020 due to:

- i. Management service agreement and management agreement entered by the Company and its wholly owned subsidiary, Shanghai Fengwei Garment Accessory Co., Ltd ("Shanghai Fengwei") with Shanghai Minlin New Textile Materials Sales Centre ("Shanghai Minlin").
- ii. Outstanding audit issue concerning Thai General Nice Coal and Coke Co., Ltd ("Thai GNCC"), a financial asset at fair value through other comprehensive income.

Please refer to page 49 & 50 of the Company's 2020 Annual Report for more information on these outstanding audit issues.

The Board has appointed KPMG Services Pte. Ltd. ("KPMG") as the independent reviewer to carry out an independent review into the above audit issues. The independent review is still ongoing as of the date of this announcement. After the conclusion of the independent review of KPMG, the Company will follow up with the appropriate accounting treatment on these outstanding audit issues.

(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

The Board confirms that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

2. Review of performance of the Group

Income Statement Review

Group revenue decreased to US\$7.36 million in the fourth quarter ended 30 June 2021 ("4Q21") compared to US\$22.26 million in 4Q20 for the continuing operations. The Group's performance has been mainly affected by a decline in demand for non-woven material as a result of heightened competition as China's economy began to recover from the Covid-19 pandemic.

Other income decreased to US\$0.20 million in 4Q21 when compared to US\$0.86 million in 4Q20 mainly due to lower in value-added tax refund and government grants received in 4Q21.

2. Review of performance of the Group (cont'd)

Income Statement Review (cont'd)

Employee benefit expenses rose to US\$2.08 million in 4Q21 from US\$1.80 million in 4Q20 on higher staff cost in the medical and dental clinics to cope with an increase in business flow.

Amortisation of intangible assets fell from US\$0.07 million in 4Q20 to US\$0.02 million in 4Q21 as the clinic management system was fully impaired in the prior financial year.

Depreciation of property, plant and equipment decreased to US\$0.02 million against US\$0.25 million previously, following a reversal of over depreciated assets.

Other operating expenses decreased to US\$1.47 million in 4Q21, down from US\$12.69 million in 4Q20 mainly due to the following items in 4Q20:

- i. Impairment loss recognised on trade and other receivables of US\$1.19 million;
- ii. Impairment loss recognised on clinic management system of US\$1.00 million; and
- iii. Consultancy and marketing fees of US\$7.68 million.

Finance costs increased to US\$0.53 million in 4Q21 from US\$0.10 million in 4Q20 mainly due to accrued interest for consideration payable to a shareholder.

Financial Position Review

Property, plant and equipment decreased to US\$3.20 million as at 30 June 2021 compared to US\$8.74 million as at 30 June 2020, reflecting the absence such immovable assets totalling US\$6.41 million held by subsidiaries that are no longer controlled by the Group. The loss was offset by the addition of a new production line in Shanghai Fengwei of US\$1.63 million.

Financial asset at fair value through other comprehensive income decreased to nil due to the loss of control of subsidiaries.

Inventories increased to US\$2.43 million as at 30 June 2021 from US\$1.91 million in the last financial year mainly due to a stock up for non-woven materials in the healthcare and healthcare consumables segment.

Trade and other receivables and contract assets decreased to US\$7.67 million when compared to US\$20.93 million as at 30 June 2020 mainly due to the loss of control of subsidiaries.

Non-current borrowings decreased to US\$3.99 million as at 30 June 2021 from US\$14.91 million as at 30 June 2020, reflecting the absence of such borrowings totalling US\$11.79 million by subsidiaries no longer controlled by the Group.

Non-current lease liabilities increased to US\$1.34 million as at 30 June 2021 from US\$0.35 million as at 30 June 2020 following a renewal of tenancy agreements by clinics and office.

Trade and other payables were lower at US\$7.82 million against US\$26.03 million as at 30 June 2020 mainly due to the loss of control of subsidiaries.

Current borrowings decreased to US\$8.58 million as at 30 June 2021 from US\$12.46 million before following the repayment of short-term loans.

2. Review of performance of the Group (cont'd)

Cash Flow Statement Review

Net cash flows used in operating activities rose to US\$3.90 million mainly resulting from the repayment of management fees of US\$3.21 million to Shanghai Minlin and payment of accrued staff cost of approximately US\$1.86 million in Shanghai Fengwei.

Net cash flows used in investing activities amounted to US\$2.44 million mainly due to additions of property, plant and equipment and intangible assets.

Net cash flows used in financing activities of US\$5.72 million were mostly to repay borrowings.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No forecast has been issued for the current financial reporting period.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

During the year under review, our medical clinics have supported the Government's programme to provide Covid 19 testings and vaccinations for local residents. This has helped to boost revenue at our healthcare subsidiary in Singapore. At the same time, we launched our Healthsciences International ("HSI") Wellness Program aimed at providing a one stop medical/dental and traditional Chinese medicine care to SMEs, family, and individuals. HSI is also exploring partnerships with other healthcare providers to complement this program to deliver a vertically integrated healthcare platform for our patients.

We are cautiously optimistic about the outlook as Singapore prepares to transition from a pandemic to an endemic mode and progressively opens up its economy and borders with easing of movement restrictions.

Overseas, our Chinese subsidiary's business has been affected by more intense competition with new players entering the healthcare non-woven manufacturing sector. Prices for non-woven materials have softened due to over-purchasing by our downstream partners. We envisage a recovery in the next quarter on a cyclical upturn in demand. The Group will also explore tapping growth opportunities in the Southeast Asia markets in the next quarter.

Management plans to launch our AI driven genomics platform in the next quarter. In conjunction with our partners, Huawei and Sensetime, we have completed proof of concept for our AI Genomics platform GEIATM and look to converting this to a PaaS cloud computing model.

After reviewing the financial forecast and cashflow projections, the Board of Directors is in the opinion that the Company and the Group can continue as a going concern and have sufficient working capital and financial resources to meet their obligations as and when they fall due for the next twelve months on the following bases and assumption:

(i) The Group had implemented several cost-cutting initiatives;

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months. (cont'd)

- (ii) The Company is alleged to be a corporate guarantor to a loan extended from OCAP Management Pte Ltd ("OCAP") to IEG. In January 2021, the Company has received letters of demand in respect of US\$7,158,133.33 from the provisional liquidators of OCAP. The Company is currently discussions and negotiations with the provisional liquidators.
- (iii) IEG is alleged to be a corporate guarantor ("NSG Guarantee") to a lease financing arrangement of the bare boat charter agreement (the "BBC agreement") entered into by its subsidiary, TXZ Tankers Pte Ltd. The Company is alleged to be a corporate guarantor to the lease financing arrangement and the contingent liabilities therein. The Company had received a letter of demand dated 7 June 2021 from Iolani Shipping Limited ("Iolani") for an alleged sum of US\$10,695,760 plus any interest which is alleged to continue to accrue in accordance with the terms of the NSG Guarantee. The Company is currently in discussions and negotiations with the counterparty.
- (iv) The Group's healthcare operations generate sufficient operating cash flows to meet its working capital requirements. The health and healthcare subsidiaries of the Company contributed US\$7.36 million to the revenue of 4Q21. The Group can continue to grow its healthcare operations based on the financials from its operating subsidiaries.
- (v) The Group also looks to launching its AI driven genomics platform in the next quarter. In conjunction with our partners, Huawei and Sensetime, we have completed our proof of concept for our AI Genomics platform GEIATM and look forward to converting this to a PaaS cloud computing model. GEIATM is a complete and seamless, hybrid cloud-based workflow platform solution with AI-optimised analyses. The Group will continue to build relationships with leading tech players who can provide us with a full range of capabilities in data-driven diagnostics.
- (vi) The Group is currently in discussions for external financing from strategic investors to the Company from the ongoing restructuring of the Company into a fully integrated healthcare business.

5. Dividend information

(a) <u>Current financial period reported on</u> Any dividend recommended for the current financial period reported on?

None.

(b) <u>Corresponding period of the immediate preceding financial year</u> Any dividend declared for the corresponding period of the immediately preceding financial year?

None.

(c) <u>Date payable</u>

Not applicable.

(d) Book closure date

Not applicable.

(e) If no dividend has been declared/recommend, a statement to the effect and the reasons for the decision

No dividend has been declared or recommend for the year ended 30 June 2021 due to accumulated losses of the Company.

6. Interested person transactions

Name of interested person	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than \$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under the shareholders' mandate pursuant to Rule 920 (excluding transactions less than \$100,000)
	US\$'000	US\$'000
Rental:		
Shanghai Fengwei Nonwovens Co, Ltd	454	-

For full disclosure, please note that there is an amount of US\$1.77M owing from Shanghai Fengwei Nonwovens Co., Ltd. ("SFNW") a company majority owned by Mr Shen Yuyun (a substantial shareholder of the Company) to Shanghai Fengwei Garment Accessory Co., Ltd. ("Shanghai Fengwei"), a wholly owned subsidiary of the Company, which amount was owing prior to the Group's acquisition of Shanghai Fengwei.

SFNW and New Silkroutes Capital Pte. Ltd. a wholly owned subsidiary has entered into a lease agreement and the amount owing from SFNW will be used to offset against the rental payable by Shanghai Fengwei for the use of the land.

7. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1)

The Company has received undertaking from all its directors and executive officers in the format as set out in Appendix 7.7 under Rule 720(1) of the Listing Manual of the SGX-ST.

8. Review of performance of the Group – turnover and earnings

During the financial year, the Group announced that it has commenced a strategic review of the Group's energy division. The review was commenced as the energy division has experienced a significant reduction in trading volumes whilst lower oil prices have also contributed to the overall drop in its trade revenues during the pandemic. The global pandemic has disrupted maritime trade and disrupted supply chains that it has made our ship chartering business non-viable.

On 5 January 2021, the Group commenced the winding up process of the wholly owned indirect subsidiary of the Company, IEG by way of creditors' voluntary liquidation and thus the Group has lost control of IEG. Accordingly, the IEG and its subsidiaries are classified as discontinued operation of the Group.

Our Chinese subsidiary's business has taken a dip due to an increase in market forces with new competitors entering the healthcare non-woven manufacturing sector in China. As we continue to battle the ongoing pandemic, the Group will review its operation and marketing strategies and stay nimble to weather the challenges ahead.

Our healthcare subsidiary has experienced robust business during the economic recovery of Singapore in the financial year.

9. Disclosure of persons occupying managerial positions who are related to a director, CEO or substantial shareholder

Pursuant to Rule 704(13) of the Listing Manual, New Silkroutes Group Limited confirms that there are no persons occupying a managerial position in the Company or in any of its principal subsidiaries who is a relative of a director, chief executive officer or substantial shareholder of the Company.

BY ORDER OF THE BOARD

Ong Beng Hong Company Secretary 27 August 2021